Skip to main content
Clinical Trials/NCT06624969
NCT06624969
Not Yet Recruiting
N/A

Virtual Reality in Reducing Acute Orthopedic Pain

Mayo Clinic0 sites100 target enrollmentMarch 1, 2026
ConditionsFractures

Overview

Phase
N/A
Intervention
Not specified
Conditions
Fractures
Sponsor
Mayo Clinic
Enrollment
100
Primary Endpoint
opioid use
Status
Not Yet Recruiting
Last Updated
4 months ago

Overview

Brief Summary

The primary aim of this research is to show that a virtual reality (VR) service line is feasible and can sustain itself with the ability to take care of patients. Additionally, the investigators aim to learn about the limitations of a service line and provide a pathway for future improvements in building a VR service line that is optimally aligned with the user's needs. Secondary aims are to evaluate the clinical aspects of the patient's outcomes including length of stay, morphine equivalents in pain medicine required during the hospital stay, and user experiences.

Registry
clinicaltrials.gov
Start Date
March 1, 2026
End Date
December 1, 2028
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Scott A. Helgeson

Consultant, Assistant Professor of Medicine

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Hospitalized with an orthopedic fracture
  • Able to participate fully in all aspects of the study
  • Able to understand and sign informed consent
  • Individuals with unaided vision or those who can correct their vision using contact lenses

Exclusion Criteria

  • Non-English speaking
  • Self-reported history of acute and/or chronic severe motion sickness
  • The presence of a facial/head deformity that will prohibit the wearing of a VR head mounted display.
  • Legally blind or deaf
  • Have had a seizure within the past 1 year
  • Have current (within the past 30 days) clinically significant acute or chronic progressive or unstable/uncontrolled neurologic disorder
  • Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence

Outcomes

Primary Outcomes

opioid use

Time Frame: From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks

Change in opioid equivalents during hospital stay from hospital admission to discharge

Secondary Outcomes

  • reduction in anxiolytics(From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks)
  • hospital length of stay(From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks)
  • reduction in sleep aids prescribed(From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks)
  • User experiences(obtained once on the day of hospital discharge, up to 5 weeks from study enrollment)

Similar Trials